NLS Pharmaceutics .(NLSP) - 2022 Q4 - Annual Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2023 (Report No. 2) Commission file number: 001-39957 SIGNATURES NLS PHARMACEUTICS LTD. (Translation of registrant's name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under ...